NuSirt Sciences Inc is a biopharmaceutical company headquartered in Nashville, TN with research labs in Knoxville, TN. Established in 2007, NuSirt focuses on developing innovative drugs for diabetes treatment and other metabolic disorders such as obesity, arteriosclerosis, and hyperlipidemia. Their leading product, NS-0100, utilizes a combination of the natural product leucine and a low dose of metformin for type II diabetes treatment. This approach aims to address the adverse gastrointestinal side effects that some patients experience with metformin, providing a potential alternative for those who cannot tolerate the traditional medication. Currently undergoing Phase 2 clinical trials to determine the most effective dosage, NuSirt's NS-0100 presents a promising alternative to metformin if successful. The company secured a $2.00M Venture Round investment on December 1, 2016. The investors involved in this round are not specified. NuSirt's innovative approach and potential market impact position it as an intriguing prospect in the biotechnology industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $2.00M | - | 01 Dec 2016 | |
| Series C | $6.00M | 4 |
|
13 May 2015 |
| Series B | $1.80M | 1 | Mountain Group Capital | 01 Jun 2014 |
| Series A | $3.50M | 2 | Tennessee Community Ventures, Mountain Group Capital | 01 Mar 2014 |
| Seed Round | $2.08M | 1 | Tennessee Community Ventures | 01 Sep 2012 |
No recent news or press coverage available for NuSirt Sciences Inc.
We care about your data, and we'd love to use cookies make your experience better.
